Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s (he’s back) Powerplays: ASX health stocks fall, Volpara ‘elephants’ strategy pays off
Health & Biotech
ScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall, Neuren’s DAYBUE drug officially rolling out in US
News
In Case You Missed It: Clay-hosted rare earths are all the rage and an Alaskan lithium player looks across the border
News
ASX Large Caps: Shares slump on RBA minutes, BlackRock ditches its 60-40 investment strategy
Health & Biotech
ASX Health Stocks: Neuren’s breakthrough Rett Syndrome drug DAYBUE is now officially available in the US
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
Three popular stocks on trading platform Stake and why investors are turning to gold
News
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?
Health & Biotech
ASX Health Stocks: Healius gets takeover offer from company less than half its size
Health & Biotech
ScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approval
News
ASX Large Caps: Aussie shares on longest losing streak since 2008; but banking crisis eases
News
ASX Large Caps: Tech stocks rally as soft US CPI points to Fed pause; market darling Neuren spikes again
News
CLOSING BELL: Who knew you could still make money from inside a burning dumpster?
News
ASX Large Caps: Shares slump 1.6pc; bond yields on free fall as traders unwind Fed hike bets
News
CLOSING BELL: And the Oscar for Best Performing Company in a Comedy Drama goes to…
News
ASX Small Caps Lunch Wrap: Who else is barely smarter than an ambulatory fungus today?
Health & Biotech